Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report

Szabolcs Bellyei1, Árpád Boronkai1, Eva Pozsgai2,3*, Dávid Fodor1 and László Mangel1

Abstract

Background: Previous studies have shown that patients who underwent renal transplantation were at a greater risk of developing malignancies. Due to advances in effective surgical techniques and immunosuppressive therapies, organ recipients live longer. Yet, there is insufficient information about the recommended type of therapy for colorectal cancer patients following transplantation. We describe the oncological treatment of a patient with renal transplantation, who presented with metastatic colon cancer 5 years after transplantation.

Case presentation: A 66-year-old Caucasian male patient, with hypertension, type 2 diabetes mellitus, paroxysmal atrial fibrillation, and renal failure underwent successful kidney transplantation in 2013. In April 2018, the adenocarcinoma of the sigmoid colon was found, and surgical resection was performed. The histological diagnosis was low-grade adenocarcinoma. Fluorodeoxyglucose positron emission tomography/computerized tomography scan showed a 2.5-cm metastasis in the VIIth segment of the liver and a metastatic paraaortical lymph node on the left. The clinical diagnosis was, therefore, metastatic (stage IV) sigmoid colon cancer (AJCC TNM system). The ongoing medications of the patient included immunosuppressive drugs and medication for his cardiovascular comorbidities. In July 2018, palliative cetuximab plus folinic acid–fluorouracil–irinotecan chemotherapeutic treatment was initiated, then cetuximab was substituted for panitumumab because of adverse events. In August 2018, the follow-up positron emission tomography/computerized tomography scan revealed stable disease. Because of side effects, the patient was unwilling to continue with the panitumumab plus folinic acid–fluorouracil–irinotecan treatment regimen. Therefore, the patient received 10×5 Gy stereotactic body irradiation for his liver metastasis and mono-panitumumab therapy. By January 2019, the positron emission tomography/computerized tomography scan showed regression of the liver metastasis but a progression in the paraaortic lymph node. Therefore, 5×8 Gy stereotactic irradiation was given to the paraaortic lesion. Meanwhile, the patient received altogether 16 cycles of panitumumab until June 2019, when complete remission was attained. In July 2019, the patient suffered a hemorrhagic stroke, probably due to his cardiovascular comorbidities, and died subsequently.
Background
Cancer is the second leading cause of death worldwide, with colorectal cancer (CRC) being the second most common cause of all cancer-related deaths [1]. Previous analyses have shown that patients who underwent renal transplantation were at a greater risk of developing malignancies such as CRC than the general population [2–5]. Following organ transplantation, patients were three times more likely to develop cancer, with an overall cancer incidence of 1.9–18% [3, 4, 6]. Since risk of carcinoma has been shown to increase with long-term use of immunosuppressant drugs, the rise in cancer incidence following transplantation is most probably caused by the prolonged use of these agents [7, 8].

Because of advances in effective surgical techniques and immunosuppressive therapies, organ recipients live longer and the survival rates of grafts have also risen [2]. The increased survival rates of these patients and their higher CRC incidence rates indicate that a growing number of recipients will likely be requiring treatment for CRC.

Pharmacotherapy, including chemotherapy and targeted treatment, has emerged as a leading form of treatment for metastatic CRC [6]. This patient group, however, provides challenges for health care professionals regarding the selection of the appropriate oncological treatment. Patients take special medication after transplantation and tend to have various medical conditions that influence the feasibility and efficacy of oncological treatments. Yet, there is insufficient information and no clear guidelines regarding the recommended types of therapy for CRC patients following transplantation.

In the present case report, we describe the oncological treatment of a patient who had previously undergone renal transplantation and presented with metastatic colon cancer 5 years later.

Case presentation
A 66-year-old Caucasian male patient, with a medical history of hypertension, type 2 diabetes mellitus (DM), paroxysmal atrial fibrillation, previous parathyroid adenoma, and renal failure of unknown origin underwent successful kidney transplantation in 2013. He did not smoke or consume alcohol and had no family history of CRC. In April 2018, he presented with abdominal discomfort at the Emergency Department. Gastroscopy showed ventricular erosions, while colonoscopy and abdominal computerized tomography (CT) scan revealed an adenocarcinoma of the sigmoid colon with minimal locoregional infiltration. Because of symptoms of bowel obstruction, urgent surgical resection was performed according to Hartmann. The histological diagnosis was low-grade adenocarcinoma, pT3 N1b (3/9+1TD), V1, Pn-, R0, N-K-Ras wild type. Fluorodeoxyglucose positron emission tomography (FDG-PET)/CT scan showed a 2.5-cm metastasis in the VIIth segment of the liver. A metastatic paraaortical lymph node on the left and raised the possibility of further smaller metastases in the liver, as well (Fig. 2a, f). Therefore, the clinical diagnosis of the patient was metastatic (stage IV) sigmoid colon cancer (AJCC TNM system). According to the multidisciplinary team (MDT), first-line palliative cetuximab plus folinic acid–fluorouracil–irinotecan (FOLFIRI) chemotherapeutic treatment was recommended.

Figure 1 shows the main events of the patient’s illness and treatment.

The ongoing medications of the patient included immunosuppressive drugs: tacrolimus, mycophenolate mofetil, and mycophenolate mofetil, as well as other drugs, losartan, pantoprazole, amlodipine, furosemide, potassium, calcitriol, atorvastatin, empagliflozin, dulaglutide, and rapid- and long-acting insulin. The patient’s body mass index was 30.9 kg/m². His Eastern Cooperative Oncology Group (ECOG) performance was 1. Prior to initiation of the treatment, the patient’s routine laboratory tests were within normal limits and his blood pressure and blood sugar values were well controlled.

Beginning July 2018, the patient received one cycle of first-line cetuximab-FOLFIRI therapy. Adverse events (AE) included fluctuations of blood sugar levels, diarrhea, and hypomagnesemia, which were treated adequately. To reduce the risk of further AE, cetuximab was substituted with panitumumab and the patient received panitumumab-FOLFIRI therapy through the second to fourth cycles of chemotherapy. The patient developed diarrhea, hypomagnesemia, and significant weight loss (5 kg) during treatment. In August 2018 the follow-up PET/CT scan revealed stable disease: regression of the
left paraaortic lymph node, no progression in the size of the liver metastasis, and no local recurrence (Fig. 2b, g).

Because of the severe AE the patient was unwilling to continue with the panitumumab-FOLFIRI treatment regimen. Ablation with radiofrequency was not a possible option for treatment. Based on the MDT’s decision, multimodal therapy, including stereotactic radiotherapy of the liver metastasis was recommended. Accordingly, in September 2018 the patient received 10×5 Gy stereotactic body irradiation (SBRT) for his liver metastasis, using the inspiration breath hold technique [9]. Since the patient did not consent to the continuation of the combination FOLFIRI treatment because of its side effects, monotherapy was initiated. Thus, the patient was given six cycles of mono-panitumumab therapy. AE, including skin rash and hypomagnesemia developed and were treated.

By January 2019, PET/CT scan showed regression of the liver metastasis but a progression in the paraaortic lymph node (Fig. 2c, d). Therefore, 5×8 Gy stereotactic irradiation (SBRT) was given to the paraaortic lesion. The follow-up PET/CT scan revealed regression in both the size and metabolic activity of the paraaortic lymph node (Fig. 2d, i). Meanwhile, the patient continued to receive mono-panitumumab therapy and altogether received 16 cycles of panitumumab until June 2019. Complete
remission was attained, since no macroscopic FDG-avid malignancy could be detected on the PET/CT scan at the end of June 2019 (Fig. 2e, j).

On 18 July 2019, the patient suffered a hemorrhagic stroke and became comatose. Despite neurosurgical intervention and intensive care, the patient died 10 days later.

Discussion
To our knowledge, this is the first case report to describe the successful chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a posttransplant patient with metastatic CRC.

According to both earlier and recent analyses, renal transplant recipients had a significantly higher incidence of CRC [2, 3, 5] and a worse 5-year survival rate than the general population [10]. Although most patients were on average shown to be diagnosed one decade after transplantation, the patient in our case received his diagnosis of CRC much earlier, only 5 years after transplantation [2]. It must be noted, however, that our patient had type 2 DM and was obese, which are conditions that have been shown to be associated with an increased risk of CRC [2, 11].

At the time of diagnosis and throughout the treatment, our patient took immunosuppressive drugs. Posttransplant patients with advanced CRC sometimes do not receive adequate therapy due to physicians’ concern about harmful interactions between immunosuppressive and chemotherapeutic agents [12]. Our patient had metastatic CRC with one liver metastasis and one paraaortic lymph node involvement; therefore, cetuximab-FOLFIRI treatment was initiated.

FOLFIRI, a combination therapy consisting of 5-Fluorouracil (5-FU), leucovorin, irinotecan, and an epidermal growth factor (EGFR) inhibitor, cetuximab, has been shown to lead to an improvement in overall survival (OS) in metastatic CRC. The addition of cetuximab to FOLFIRI treatment has shown to increase OS from 15 to 18.5 months in right-sided tumors and from 21 to 28 months in left-sided tumors according to the CRYSTAL trial and from 15 to 18.3 months and 21.7 to 38.3 months in right- and left-sided tumors, respectively, according to the results of the FIRE-3 trial [13, 14]. The hypomagnesemia previously reported as an AE of cetuximab therapy [15, 16] was observed in our patient as well. Since our patient also developed fluctuations in blood sugar levels, biological treatment with the chimeric monoclonal antibody, cetuximab, was substituted with the fully human monoclonal antibody, panitumumab, in the subsequent cycles of FOLFIRI plus targeted therapy treatment. Although the follow-up PET/CT scan showed stable disease after four cycles of FOLFIRI plus targeted therapy, our patient could not continue the regimen because of intolerance (diarrhea and resulting significant weight loss) of the irinotecan-based chemotherapy. Therefore, the SBRT of the liver metastasis was carried out followed by subsequent cycles of panitumumab and irradiation of the paraaortic lymph node. Since systemic chemotherapy has been shown to improve patient survival in stage IV CRC, the relevance of the successful local treatment of oligometastases has also increased [17]. SBRT treatment of oligometastatic disease, characterized by an excellent safety profile, can efficiently complement systemic therapy, as was found in our patient’s case. The decision was in line with the current guidelines (NCCN Guidelines, colon cancer, Version 4.220). The associated adverse effects of panitumumab, skin rash, and decreased magnesium levels [18] developed in our patient’s case but were tolerable and could be treated adequately. Sixteen cycles of panitumumab as mono-treatment were successfully given, and follow-up was performed using PET/CT scans at regular intervals.

Thirteen months after diagnosis of metastatic CRC in our posttransplant patient, we were able to achieve complete remission. The patient subsequently died from a hemorrhagic stroke. The cause of his death was considered to be the result of his cardiovascular comorbidities and not due to the oncological treatment he received.

Conclusions
Based on a growing number of studies, it appears crucial that recommendations for CRC screening be developed and implemented for posttransplant patients. Likewise, it is of considerable importance that these patients receive adequate treatment for CRC. Since information and guidelines are lacking regarding the treatment of patients after transplantation, data about their oncological treatment are essential. Our case report is valuable since we described the case of a metastatic CRC patient with renal transplant, where the use of chemotherapy was limited yet complete remission could be attained by using biological (targeted) treatment and radiotherapy.

Abbreviations
CRC: Colorectal cancer; 2 DM: Type 2 diabetes mellitus; MDT: Multidisciplinary team; ECOG: Eastern Cooperative Oncology Group; AE: Adverse events; SBRT: Stereotactic body irradiation; 5-FU: 5-Fluorouracil; EGFR: Epidermal growth factor; OS: Overall survival.

Acknowledgements
We would like to thank the patient, who, in the course of his treatment, strongly encouraged the writing of this case because of his great knowledge and interest in science.

Authors’ contributions
All authors were involved in delivery of the investigation. They have all read and approved the final manuscript: SB, AB, and LM participated in the treatment of the patient. SB, LM, EP, and DF analyzed the patient’s data...
and relevant literature and prepared the manuscript. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethics committee approval was obtained from the Regional Ethical Committee (Reference number: 7532-PTE2019).

Consent for publication
Written informed consent was obtained from the patient’s relative for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Oncotherapy, Clinical Center, University of Pécs, Edesanyák Street 10, 7624 Pécs, Hungary. 2 Department of Public Health, Medical School, University of Pécs, Szígenti Street 12, 7624 Pécs, Hungary. 3 Institute of Primary Health Care, Medical School, University of Pécs, Rákóczi Street 2, 7623 Pécs, Hungary.

Received: 12 December 2020   Accepted: 27 January 2021
Published online: 20 March 2021

References
1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
2. Balhareth A, Reynolds IS, Solon JG, Harte EG, Boland F, O’Sullivan JM, et al. Thirty-seven-year population-based study of colorectal cancer rates in renal transplant recipients in Ireland. Transplant Proc. 2018;50(10):3434–9.
3. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140(2):197–208.
4. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55(4):742–7.
5. Wang HE, Liao YC, Hu JM, Wu WC, Chou WY, Chen YC, et al. Correlation between kidney transplantation and colorectal cancer in hemodialysis patients: A nationwide, retrospective, population-based cohort study. BMC Cancer. 2019;19:1.
6. Saidi RF, Dudrick PS, Goldman MH. Colorectal cancer after renal transplantation. Transplant Proc. 2003;35(4):1410–2.
7. Demir T, Ozel L, Gökçe AM, Ata F, Kara M, Eriş C, et al. Cancer screening of renal transplant patients undergoing long-term immunosuppressive therapy. Transplant Proc. New York: Elsevier; 2015. p. 1413–7.
8. Agraharkar ML, Cincirad RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int. 2004;66(1):383–9.
9. Mast M, Kouwenhoven E, Roos J, van Geen S, van Egmond J, van Santvoort J, et al. Two years’ experience with inspiration breath-hold in liver SBRT. Tech Innov Patient Support Radiat Oncol. 2018;7:1–5.
10. Liu HY, Liang XB, Li YF, Feng Y, Liu DB, Da WW. Treatment of advanced rectal cancer after renal transplantation. World J Gastroenterol. 2011;17(15):2058–60.
11. Peeters PHL, Bazelier MT, Leufkens HGM, De Vries F, De Bruin ML. The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. Diabetes Care. 2015;38(9):502–5.
12. Fang W. Chemotherapy in patient with colon cancer after renal transplantation: a case report with literature review. Medicine (Baltimore). 2017;96:1.
13. Arnold D, Lusea B, Douillard JY, Peerers M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.
14. Tejpar S, Stintzing S, Gardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with ras wild-type metastatic colorectal cancer retrospective analyses of the CRYSTAL and FIRE-3 trials. In: JAMA Oncol. American Medical Association; 2017. p. 194–201.
15. Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfaro F, Silletta M, et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res. 2008;14(13):4219–24.
16. Vickers MM, Karapetis CS, Tu D, O’Callaghan CJ, Price TJ, Tebbutt NC, et al. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO17. Ann Oncol. 2013;24(4):953–60.
17. Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol. 2014;20(15):4220–9.
18. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.